The burgeoning UK environment surrounding entheogens is increasingly complex, demanding careful assessment. While therapeutic investigation into compounds like psilocybin and copyright continues to progress, and patient availability via private clinics is growing, the regulatory framework remains ambiguous. This presents a challenging situation for